Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1993 1
1994 1
1995 2
1996 3
1997 4
1998 7
1999 3
2000 10
2001 7
2002 7
2003 7
2004 12
2005 7
2006 11
2007 13
2008 15
2009 11
2010 14
2011 15
2012 13
2013 29
2014 39
2015 53
2016 45
2017 37
2018 46
2019 41
2020 46
2021 61
2022 68
2023 69
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Results by year

Filters applied: . Clear all
Page 1
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND. Freedland SJ, et al. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974. N Engl J Med. 2023. PMID: 37851874 Clinical Trial.
No new safety signals were observed, with no substantial between-group differences in quality-of-life measures. CONCLUSIONS: In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with re …
No new safety signals were observed, with no substantial between-group differences in quality-of-life measures. CONCLUSIONS: I …
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.
Huang DQ, El-Serag HB, Loomba R. Huang DQ, et al. Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):223-238. doi: 10.1038/s41575-020-00381-6. Epub 2020 Dec 21. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33349658 Free PMC article. Review.
Although the incidence of NAFLD-related HCC is lower than that of HCC of other aetiologies such as hepatitis C, more people have NAFLD than other liver diseases. Urgent measures that increase global awareness and tackle the metabolic risk factors are necessary to reduce th …
Although the incidence of NAFLD-related HCC is lower than that of HCC of other aetiologies such as hepatitis C, more people have NAFLD than …
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.
Huang DQ, Singal AG, Kanwal F, Lampertico P, Buti M, Sirlin CB, Nguyen MH, Loomba R. Huang DQ, et al. Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37537332 Review.
In particular, more than one-third of patients with HCC related to non-alcoholic fatty liver disease do not have cirrhosis and therefore lack a routine indication for HCC surveillance on the basis of current practice guidelines. Semi-annual abdominal ultrasound with measuremen …
In particular, more than one-third of patients with HCC related to non-alcoholic fatty liver disease do not have cirrhosis and therefore lac …
Quality of life in "chronic" cancer survivors: a meta-analysis.
Firkins J, Hansen L, Driessnack M, Dieckmann N. Firkins J, et al. J Cancer Surviv. 2020 Aug;14(4):504-517. doi: 10.1007/s11764-020-00869-9. Epub 2020 Mar 11. J Cancer Surviv. 2020. PMID: 32162194 Review.
Standardized effect sizes and errors were calculated using previously published standard QOL pass rates to compare QOL across measurement tools and calculate cumulative effect sizes (CES). Fixed-effect or random-effects models were used based on the presence of significant …
Standardized effect sizes and errors were calculated using previously published standard QOL pass rates to compare QOL across measurement …
Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
Gulati S, Eckman MH. Gulati S, et al. Ann Intern Med. 2023 Jan;176(1):1-9. doi: 10.7326/M22-1258. Epub 2022 Dec 27. Ann Intern Med. 2023. PMID: 36571839 Free PMC article.
INTERVENTION: Strategies of 1) enoxaparin, 2) apixaban, 3) edoxaban, and 4) rivaroxaban for treatment of CAT. OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER) in 2022 U.S. dollars per quality-adjusted life-year (QALY) gained. RESULTS OF BASE-CASE ANALYS …
INTERVENTION: Strategies of 1) enoxaparin, 2) apixaban, 3) edoxaban, and 4) rivaroxaban for treatment of CAT. OUTCOME MEASURES: Incre …
Association Between Surgical Quality Metric Adherence and Overall Survival Among US Veterans With Early-Stage Non-Small Cell Lung Cancer.
Heiden BT, Eaton DB Jr, Chang SH, Yan Y, Baumann AA, Schoen MW, Tohmasi S, Rossetti NE, Patel MR, Kreisel D, Nava RG, Meyers BF, Kozower BD, Puri V. Heiden BT, et al. JAMA Surg. 2023 Mar 1;158(3):293-301. doi: 10.1001/jamasurg.2022.6826. JAMA Surg. 2023. PMID: 36652269 Free PMC article.
MAIN OUTCOMES AND MEASURES: Overall survival and RFS. RESULTS: The study included 9628 veterans who underwent surgical treatment between 2006 and 2016. ...The median (IQR) follow-up time was 6.2 (2.5-11.4) years. An integer-based score (termed the Veterans Af …
MAIN OUTCOMES AND MEASURES: Overall survival and RFS. RESULTS: The study included 9628 veterans who underwent surgical treatme …
Evaluation of the Measuring and Improving Quality in Palliative Care Survey.
Dy SM, Sharma R, Kuchinad K, Liew ZR, Abu Al Hamayel N, Hannum SM, Zhu J, Kamal AH, Walling AM, Lorenz KA, Isenberg SR. Dy SM, et al. J Oncol Pract. 2018 Dec;14(12):e834-e843. doi: 10.1200/JOP.18.00405. J Oncol Pract. 2018. PMID: 30537461 Free PMC article.
Results varied across sites by more than 1 point on the 1 to 5 scales between the 10th and 90th percentiles of sites for two constructs in recognition and focus on quality measurement (score range by site, 1.7 to 4.8), one construct in teamwork (score range, 3.1 to …
Results varied across sites by more than 1 point on the 1 to 5 scales between the 10th and 90th percentiles of sites for two constructs in r …
Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Quality Measures Initiative.
Park J, Puckett LL, Katsoulakis E, Venkatesulu BP, Kujundzic K, Solanki AA, Movsas B, Simone CB 2nd, Sandler H, Lawton CA, Das P, Wo JY, Buchholz TA, Fisher CM, Harrison LB, Sher DJ, Kapoor R, Chapman CH, Dawes S, Kudner R, Wilson E, Hagan M, Palta J, Kelly MD. Park J, et al. Pract Radiat Oncol. 2022 Nov-Dec;12(6):468-474. doi: 10.1016/j.prro.2022.05.015. Epub 2022 Jun 8. Pract Radiat Oncol. 2022. PMID: 35690354
As a part of the largest integrated health system in America, the Department of Veterans Affairs National Radiation Oncology Program (VA-NROP) established a quality surveillance initiative to address the challenge and necessity of providing the highest quality …
As a part of the largest integrated health system in America, the Department of Veterans Affairs National Radiation Oncology Program …
Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.
Kutner JS, Blatchford PJ, Taylor DH Jr, Ritchie CS, Bull JH, Fairclough DL, Hanson LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA, McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA, Swetz KM, Von Gunten CF, Abernethy AP. Kutner JS, et al. JAMA Intern Med. 2015 May;175(5):691-700. doi: 10.1001/jamainternmed.2015.0289. JAMA Intern Med. 2015. PMID: 25798575 Free PMC article. Clinical Trial.
Patients in the continuation group continued to receive statins. MAIN OUTCOMES AND MEASURES: Outcomes included death within 60 days (primary outcome), survival, cardiovascular events, performance status, quality of life (QOL), symptoms, number of nonstatin medicatio …
Patients in the continuation group continued to receive statins. MAIN OUTCOMES AND MEASURES: Outcomes included death within 60 days ( …
Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.
Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Blakeley JO, et al. Neuro Oncol. 2016 Mar;18 Suppl 2(Suppl 2):ii13-ii20. doi: 10.1093/neuonc/nov291. Neuro Oncol. 2016. PMID: 26989128 Free PMC article. Review.
Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall sur …
Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outc …
615 results